News

The Scientist1d
Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...
Medical Device Network on MSN2d
FDA grants 510(k) clearance to Fujirebio’s blood-based test for Alzheimer’s
The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...
FDA greenlights marketing of first Alzheimer's blood test for some patients
Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...
MedPage Today5d
FDA Clears First Blood Test for Alzheimer's Diagnosis
The blood test, known as the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio, can be used to detect amyloid plaques ...
FDA greenlights first blood test to help diagnose Alzheimer’s disease in the US
The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...
Morningstar1mon
ARUP Launches pTau 217 Blood Test To Detect Alzheimer's Disease Pathology
SALT LAKE CITY, April 21, 2025 /PRNewswire/ -- ARUP Laboratories now provides a blood test for phosphorylated tau 217 (pTau 217) to assist in identifying whether cognitive decline symptoms in ...
Yahoo Finance29d
ARUP announces blood test to identify Alzheimer’s pathology
ARUP Laboratories has introduced a blood test for phosphorylated tau 217 (pTau 217) to aid in diagnosing the pathology of Alzheimer's disease in individuals aged 60 years and above experiencing ...
Mena FN4d
Fujirebio Receives Marketing Clearance For Lumipulse® G Ptau 217/ Β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test A...
(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...